AAO: Study confirms Phase III results for uveitis treatment

Video
Conference|AAO

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Related Content
A black background with a red line graph going down. Image credit: ©Who is Danny – stock.adobe.com

Increase in the incidence rate of conjunctival melanoma in Australia

March 28th 2024
Article

Investigators analysed the incidence and mortality rates from conjunctival melanoma cases over a 32-year period

A man is on the phone next to the aftermath of a car accident. Image credit: ©Southworks – stock.adobe.com

Assessing long-term impact of ocular injuries after motor vehicle accidents

March 18th 2024
Article

Researchers investigated patients' ability to drive and work following eye injury

An elderly woman clutches her forehead in pain. Image credit: ©Tom Wang – stock.adobe.com

COPHy 2024: Should all elderly patients with acute visual loss go to the emergency department?

March 16th 2024
Article

A case study emphasises the shifting paradigm in clinical best practices

A sign outside the US FDA office. Image credit: ©JHVEPhoto – stock.adobe.com

United States FDA approves clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals and AimMax Therapeutics

March 5th 2024
Article

The approval marks the first new steroid on the US ophthalmic market in more than 15 years

Three women in lab coats face away from the viewer. Over their heads, text reads, "Where Women Stand."

Where women stand: A progress report on gender equity in ophthalmology

March 1st 2024
Article

Mentorship, leadership and addressing bias are key areas for improvement

Angiogenesis 2024: Interim findings of phase 2 RIPPLE-1 trial on intravitreal dexamethasone implant for DMO and RVO

Angiogenesis 2024: Interim findings of phase 2 RIPPLE-1 trial on intravitreal dexamethasone implant for DMO and RVO

February 4th 2024
Article

Dr Baruch Kuppermann discusses interim results from the first in-human Phase 2 RIPPLE-1 Trial of a dexamethasone implant for diabetic macular oedema and retinal vein occlusion.

© 2024 MJH Life Sciences

All rights reserved.